Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Debt / NOTE 1.000%11/1
-
Number of holders
-
39
-
Total 13F principal, excl. options
-
461,458,000
-
Principal change
-
+37,263,000
-
Total reported value, excl. options
-
$421,344,894
-
Value change
-
+$26,191,596
-
Number of buys
-
21
-
Number of sells
-
-17
-
Price
-
$0.9113
Significant Holders of ISIS PHARMACEUTICALS INC DEL - NOTE 1.000%11/1 as of Q1 2016
48 filings reported holding 464337AJ3 - ISIS PHARMACEUTICALS INC DEL - NOTE 1.000%11/1 as of Q1 2016.
ISIS PHARMACEUTICALS INC DEL - NOTE 1.000%11/1 has 39 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $461,458,000 of principal
.
Largest 10 bondholders include ADVENT CAPITAL MANAGEMENT /DE/ ($81,578,000 of principal), CITADEL ADVISORS LLC ($57,500,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($37,810,000 of principal), JPMORGAN CHASE & CO ($27,053,000 of principal), CALAMOS ADVISORS LLC ($22,479,000 of principal), UBS ASSET MANAGEMENT AMERICAS INC ($22,000,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($20,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($18,000,000 of principal), Invesco Ltd. ($15,000,000 of principal), and SONORA INVESTMENT MANAGEMENT, LLC ($13,485,000 of principal).
This table shows the top 39 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.